Matthew Stachler

Molecular Pathologist and Researcher of pre-malignant gastrointestinal diseases

[Esophageal Cancer RF @SalgiFoundation]

Your donation matters! Dr. Stachler of @UCSF expressed gratitude for the research funding he was awarded.

To donate in support of esophageal cancer research, visit: https://t.co/lyuw3BWwNv

To read more about Dr. Stachler's research, please visit: https://t.co/42GNU8MOrd

[Chris Jones @DrCMJones]

Registration now open for #CamSOC2024 - https://t.co/pS1NbYa09z. Come and join us and a fantastic line up of speakers, including @RFitzgerald_lab @MatthewStachler @mcdona02 @Chumduri @trevoragraham @derks_s @RussellPetty19 @YJanjigianMD @KarynAGoodman @StevenLin_MDPhD.

[Matthew Stachler @MatthewStachler]

Interesting study showing many cases of "recurrent" Barrett's esophagus after endoscopic therapy is actually residual disease. Highly collaborative effort!!

Clinical and Translational Gastroenterology https://t.co/dUl1aYw6b1

[Matthew Stachler @MatthewStachler]

Excited to show some of our work in spatial profiling. This was just the pilot phase of the experiment, but the results look promising.

https://t.co/fTRForIrEv

[Matthew Stachler @MatthewStachler]

Frustrating but after 2 yrs, three rounds of review, and 2/3 positive reviewers our manuscript has been rejected at Nature Genetics. Not sure this is sustainable. On the plus side, it has given us a chance to update the BioRxiv version. Check it out.

https://t.co/6Kp2sRuTC8

[Matthew Stachler @MatthewStachler]

https://t.co/ItI7xApb23

[Matthew Stachler @MatthewStachler]

Great esophageal and gastric cancer conference. Some great talks and networking opportunities!

[Matthew Stachler @MatthewStachler]

If you are going to submit a manuscript for publication, please review for grammar and labeling errors. Mistakes will happen (my grammar is terrible) but they shouldn’t make the paper unreadable. 😡

[Matthew Stachler @MatthewStachler]

@MattGosseMD @GIPathJC Our clinical information was somewhat limited (no BE length) and in the retrospective cohort controlled for age. We didn’t identify any other factors that correlated with staining. A deep dive into the histology could be interesting to see if there is something there.

[Matthew Stachler @MatthewStachler]

@GIPathJC Thank you for having me. I hope our study is useful. We have several other interesting projects in the pipeline looking at genomic and epigenomic alterations as biomarkers. Always looking for potential collaborations!

[Matthew Stachler @MatthewStachler]

@GILiverPancreas @GIPathJC In our study no patient had a visible lesion, though as endoscopies improve more and more low-grade dysplasia is visible. We don't use that as a criteria but I can't say for certain what the gastroenterologists use to make their final decision

[Matthew Stachler @MatthewStachler]

@GIPathJC I think you will lose sensitivity if you do not stain every block with BE in it. Definitely an area for further study

[Matthew Stachler @MatthewStachler]

@GIPathJC That is a really good question and one that I don't think is fully answered. In our study we tried to stain every BE block we could and counted the endoscopy + if any one of them had abnormal p53. We definitely had cases were not every block was positive.

[Matthew Stachler @MatthewStachler]

@GIPathJC Many disagree but I have a problem with ablation for all LGD patients. I think using p53 IHC to substratify LGD is likely the lowest hurdle

[Matthew Stachler @MatthewStachler]

@GIPathJC I could see more requests coming in. I think if you take our study in the context of all of the previous work, there is now reasonable evidence for it. Any different clone should be tested to see if they perform similarly.

[Matthew Stachler @MatthewStachler]

@GIPathJC Like any more complex interpretation (HER2,...) it takes a little practice, but we did not run into too many difficulties. There were cases termed "indefinite staining" with some 2-3+ but <50%. We counted all of those as negative which seemed to work better than a lower cutoff

[Matthew Stachler @MatthewStachler]

@GIPathJC In areas of increased proliferation one can see slightly elevated p53 staining. In those cases it helps if you can see the staining outside of the normal proliferative zone

[Matthew Stachler @MatthewStachler]

@GIPathJC Its interesting, people have been using p53 as a marker for dysplasia but in reality I think it is a marker for progression risk not necessarily dysplasia. However, if one assumes the vast majority of non-dysplastic BE is low risk, using it as help in IND diagnosis is reasonable

[Matthew Stachler @MatthewStachler]

@GIPathJC Hi everyone. Hope you found the study interesting. It took awhile to put all of the pieces together but I think it was worth it.

[Pallavi A. Patil, MD @PAPatilMD]

#Tweeps #GIPathJC is today!
-Tune in at #GIPathJC in Twitter search box at 8:30 pm EST
#GIpath #pathology
-Make sure to tag questions and comments with #GIPathJC to be visible in the discussion
-Guest expert @MatthewStachler of @UCSF

-@AGA_Gastro link https://t.co/GKa9FN3rwH